Tools, Biomarkers Needed to Identify Immune-Related Toxicities
This video reviews the need for biomarkers and tools that could identify those at high risk of immune-related toxicities among patients undergoing immunotherapy treatment.
In this video, Vamsidhar Velcheti, MD, of the Cleveland Clinic in Cleveland, Ohio, discusses the need for tools and biomarkers to identify those at high risk of immune-related toxicities among patients undergoing immunotherapy treatment, and reviews some of the dangerous toxicities that can occur.
Velcheti gave a presentation on this topic earlier this year during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Recent Videos
Related Content
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
